High materiality7/10
Odyssey Therapeutics initiated with a Buy at UBS
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS initiates Odyssey Therapeutics (ODTX) with a Buy rating. Target is $27 vs a current price of $19, suggesting meaningful upside potential.
- UBS initiates ODTX with Buy; target $27; price $19.
- Upside potential substantial.
Key facts
- 01
Target: $27
- 02
Posted price: $19
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.